CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.126
https://www.valueinhealthjournal.com/article/S1098-3015(23)03256-4/fulltext
Title : CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03256-4&doi=10.1016/j.jval.2023.09.126
First page :
Section Title :
Open access? : No
Section Order : 10718
Categories :
Tags :
Regions :
ViH Article Tags :